Building a new discovery paradigm to unlock intractable drug targets with exosites
Location: United States, Massachusetts, Watertown
Employees: 11-50
Total raised: $103M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | Newpath Ma... | newpath.pa... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.10.2021 | Series B | $78M | - |
| 16.12.2020 | - | $25M | - |
Mentions in press and media 3
| Date | Title | Description |
| 11.10.2021 | Exo Therapeutics Raises $78M in Series B Financing | Exo Therapeutics, Inc., a Cambridge, Mass.-based small molecule drug discovery and development company, closed a $78m Series B financing. The round was led by new investor Nextech Invest with participation from BVF Partners, Samsara Biocapi... |
| 16.12.2020 | Exo Therapeutics snags $25M to handle 'undruggable' enzymes through their exosites W h i t e p a p e r Weighing the Costs: | Michael Bruce, Ph.D., has worked for the likes of Pfizer and CRISPR Therapeutics, but now he’s the CEO of what he believes will be the future in medicine: Exo Therapeutics. The company raised $25 million (PDF) in series A funding to back a ... |
| 16.12.2020 | Exo Therapeutics snags $25M to handle 'undruggable' enzymes through their exosites | Michael Bruce, Ph.D., has worked for the likes of Pfizer and CRISPR Therapeutics, but now he’s the CEO of what he believes will be the future in medicine: Exo Therapeutics. The company raised $25 million (PDF) in series A funding to back a ... |